Allows terminally ill patients in Hawaii to access investigational drugs or biological products.
The bill allows terminally ill patients in Hawaii to access investigational drugs or biological products that have completed phase one of FDA clinical trials. Manufacturers can offer these products at no cost or charge the manufacturing costs. Patients must meet specific criteria, including having a terminal illness diagnosis and considering all approved treatments. Health insurers can deny coverage for the investigational treatment but must cover preexisting conditions and benefits started before treatment. The bill also protects patients' heirs from liability for treatment-related debts.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.